SFL Pharmaceuticals Deutschland GmbH
4 products tracked · names used in filings: SFL Pharmaceuticals Deutschland GmbH
Upcoming milestones
Aumseqa (Aumolertinib): expected EC decision
Estimated as CHMP opinion (2026-11-12) + 67 days, the standard Commission decision period. Not an official date. · SFL Pharmaceuticals Deutschland GmbH · source
Gevalka (ensartinib): expected EC decision
Estimated as CHMP opinion (2026-09-17) + 67 days, the standard Commission decision period. Not an official date. · SFL Pharmaceuticals Deutschland GmbH · source
Recent milestones
Aumseqa (Aumolertinib): CHMP positive opinion
Gevalka (ensartinib): CHMP positive opinion
Aumseqa (Aumolertinib) approved in the EU
Marketing authorisation to SFL Pharmaceuticals Deutschland GmbH; Additional monitoring · source
Aumseqa (Aumolertinib): CHMP positive opinion
SFL Pharmaceuticals Deutschland GmbH; Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Aumseqa Aumolertinib | Opinion | |
| 🇪🇺 | Gevalka ensartinib | Opinion | |
| 🇪🇺 | Aumseqa Aumolertinib | Revoked | 2026-02-12 |
| 🇪🇺 | Nyxthracis (previously Obiltoxaximab SFL) obiltoxaximab | Withdrawn | 2020-11-18 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.